Exercise & Muscle
    Retatrutide

    Retatrutide and Creatine: Should You Supplement?

    Creatine is the most researched and effective supplement for muscle preservation. When you are losing 20-24% of your body weight on retatrutide, it may be one of the smartest additions to your regimen. Here is what the evidence says.

    Published: April 3, 202612 min read

    Muscle preservation is one of the top concerns for patients on GLP-1-based weight loss medications. With retatrutide producing up to 24% body weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023), the need for effective muscle-preserving strategies is greater than ever. Among all available supplements, creatine monohydrate stands alone in its evidence base for supporting muscle mass, strength, and cellular health during caloric deficit.

    The question is not whether creatine works -- decades of research have established that conclusively. The question is whether it makes sense specifically for patients taking retatrutide, whether there are any interactions to consider, and how to use it practically during rapid weight loss.

    Supplement Disclaimer

    Supplements are not a substitute for proper nutrition, exercise, or medical treatment. Always inform your healthcare provider about all supplements before starting. Retatrutide is an investigational drug not yet FDA-approved.

    What Creatine Actually Does

    Creatine is a naturally occurring compound found in muscle cells. Your body produces about 1-2 grams daily from amino acids, and you consume additional creatine from meat and fish. Supplementation increases the total creatine stored in your muscles, which provides several benefits:

    • ATP regeneration: Creatine donates a phosphate group to regenerate ATP (adenosine triphosphate), the primary energy currency for short-duration, high-intensity muscle contractions. This allows you to perform more reps and lift heavier loads.
    • Cellular hydration: Creatine draws water into muscle cells, creating a more anabolic environment. This intracellular hydration supports protein synthesis and inhibits protein breakdown.
    • Muscle protein synthesis: Several studies suggest creatine directly enhances muscle protein synthesis, independent of its energy effects. This is particularly valuable during caloric deficit when protein synthesis is already compromised.
    • Satellite cell activation: Creatine may increase the number and activity of satellite cells, which are muscle stem cells involved in repair and growth.

    Why Creatine Matters Specifically on Retatrutide

    The case for creatine supplementation becomes stronger, not weaker, during medication-assisted weight loss. Several factors unique to the retatrutide context make creatine particularly relevant:

    Why Creatine Is Especially Valuable on Retatrutide

    Caloric Deficit Amplification

    Retatrutide creates a profound caloric deficit. During deficit, creatine's ability to support ATP regeneration becomes more critical because the body has fewer dietary calories available for muscle energy. Creatine helps you maintain training performance even when eating less.

    Reduced Meat Intake

    Many patients on GLP-1 medications report reduced appetite for meat specifically. Since creatine in the diet comes primarily from animal products, supplementation compensates for the dietary creatine you may be missing.

    Glucagon Counterbalance

    Retatrutide's glucagon component promotes amino acid catabolism. Creatine's muscle-protective effects at the cellular level may help counteract any glucagon-driven increase in muscle protein breakdown.

    Training Performance

    When energy is limited by reduced food intake, training performance typically declines. Creatine helps maintain strength and training quality, which in turn maintains the muscle-preserving stimulus of resistance training.

    How to Take Creatine on Retatrutide

    Dosing Protocol

    • Daily dose: 3-5 grams of creatine monohydrate per day
    • Loading phase: Not necessary. Daily dosing at 3-5 grams will fully saturate muscle stores within 3-4 weeks. Loading (20 grams/day for 5 days) is optional and can cause GI discomfort, which is especially undesirable when retatrutide may already cause GI symptoms.
    • Timing: Take at any consistent time of day. Post-workout with a protein source is slightly optimal but the difference is minimal compared to simply taking it daily.
    • Mixing: Creatine monohydrate dissolves well in water, juice, or protein shakes. It is flavorless and odorless.

    What to Expect

    • Week 1-2: Water weight increase of 2-4 pounds. This is intracellular water in muscle cells, not fat. Do not be alarmed if the scale goes up slightly.
    • Week 3-4: Full muscle creatine saturation achieved. You may notice improved training endurance and the ability to complete more reps.
    • Ongoing: Maintenance of muscle hydration and training performance throughout your weight loss journey.

    Safety Considerations

    Creatine Safety Profile

    Drug Interactions

    No known interactions with GLP-1 receptor agonists, GIP agonists, or glucagon receptor agonists. Creatine works at the muscle cell level and does not interfere with the hormonal pathways targeted by retatrutide.

    Kidney Function

    Creatine does not damage healthy kidneys. However, it naturally elevates serum creatinine, a lab marker used to assess kidney function. Inform your provider you take creatine so they do not misinterpret elevated creatinine as kidney damage.

    GI Tolerance

    Creatine at standard doses (3-5 grams) is generally well-tolerated. Loading doses (20 grams) can cause bloating and diarrhea. Given that retatrutide may already cause GI symptoms, skip the loading phase and use the standard daily dose.

    Hydration

    Creatine increases intracellular water needs. Ensure adequate hydration (at least 64 ounces of water daily), which is already important on GLP-1 medications that can increase dehydration risk.

    Who Should and Should Not Consider Creatine

    Strong Candidates

    • Patients performing resistance training 2+ times per week
    • Patients concerned about muscle preservation during rapid weight loss
    • Patients who have reduced meat consumption due to appetite changes
    • Adults over 50 with increased sarcopenia risk

    Use Caution

    • Patients with pre-existing kidney disease (consult nephrologist first)
    • Patients taking nephrotoxic medications (discuss with provider)
    • Patients who experience significant GI symptoms from creatine at any dose

    The Bottom Line

    Creatine monohydrate at 3-5 grams daily is a safe, inexpensive, and evidence-backed supplement that can support muscle preservation during retatrutide-assisted weight loss. It works best when combined with resistance training and adequate protein intake. There are no known interactions with GLP-1-based medications, and the decades-long safety record makes it one of the most reliable supplements available.

    For patients on retatrutide who are performing resistance training, creatine should be near the top of the supplement consideration list -- ahead of BCAAs, fat burners, and most other marketed supplements that have far less evidence supporting their use.

    To explore currently available weight loss treatment options, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not yet approved by the FDA. Supplement recommendations should be discussed with your healthcare provider. Creatine may affect laboratory values (serum creatinine). Clinical data referenced is from Phase 2 trials (Jastreboff et al., NEJM 2023). Consult with a licensed healthcare provider before starting any supplement regimen.

    Start Your Weight Loss Journey

    Medically guided weight loss with expert support. Get matched with a provider today.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 18, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.

    FDA approved oral Wegovy (semaglutide 50mg tablet) for weight loss in 2026. Review covers clinical trial results (~15% body weight loss), dosing, side effects, cost ($1,000–$1,500/mo), and affordable injectable alternatives.

    Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.

    Complete guide covering finding the best online weight loss doctors in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredients at u

    Start your GLP-1 journey — from $99/mo

    Get Started